Date: Dec 20, 2012 Source: Yahoo Finance (
click here to go to the source)
HERCULES, CA--(Marketwire - Dec 20, 2012) - Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostic products, today announced that they have entered into an agreement with Lamprogen, Inc. Under the terms of the agreement, Lamprogen grants Bio-Rad exclusive rights to commercialize a class of bright, stable, and non-toxic fluorescent particles for use in a broad array of assays and research applications including flow cytometry. Bio-Rad expects commercialization of the particles in 2013. As part of the agreement, Bio-Rad will also have access to future technologies developed by Lamprogen.
"Combining Lamprogen's unique fluorescent particles with antibodies or other biomolecules will enable our customers to create single and multiplex assays with greater detection capabilities," said Brad Crutchfield, Bio-Rad EVP and President, Life Science Group.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.B) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The Company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 100,000 research and industry customers worldwide through its global network of operations. The company employs over 7,100 people globally and had revenues exceeding $2 billion in 2011. For more information, please visit www.bio-rad.com.
